Fontana, Pierre

 
Title Year Hits Downloads
Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model 2018 75 4
Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT 2018 52 2
Angiologie et hémostase 2017 57 27
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation 2017 63 0
Subthalamic nucleus deep brain stimulation for Parkinson's disease in a patient with severe haemophilia A. 2017 57 0
Impact of rivaroxaban on point-of-care assays 2017 78 0
TiN x O y coatings facilitate the initial adhesion of osteoblasts to create a suitable environment for their proliferation and the recruitment of endothelial cells 2017 96 2
Platelets in liver regeneration 2017 61 2
Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015 2017 95 0
Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring 2017 73 10
Pannexin- and Connexin-Mediated Intercellular Communication in Platelet Function 2017 92 37
Impact of pneumatic tube system transport for the monitoring of heparin therapy 2017 53 0
Pannexin1 Single Nucleotide Polymorphism and Platelet Reactivity in a Cohort of Cardiovascular Patients 2017 110 1
Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients? 2017 59 0
Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study 2017 52 0
Platelet reactivity in stable cardiovascular patients with chronic kidney disease 2017 85 0
A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system 2017 104 3
Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels 2017 55 0
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies 2016 237 1
PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients 2016 102 0
Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis 2016 269 123
TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke 2016 109 0
News in angiology and hemostasis 2016 202 75
Modulation of osteoblast behavior on TiNxOy coatings by altering the N/O stoichiometry while maintaining a high thrombogenic potential 2016 173 3
Correction of prasugrel-related bleeding by prophylactic transfusion of human platelets in a rabbit model 2016 94 2
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data 2016 159 2
Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study 2016 100 0
New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach 2016 238 6
Genetic testing to identify women at risk of venous thromboembolism with contraceptive pills: Evidence or hope-based tool ? 2016 148 53
Direct oral anticoagulants: a guide for daily practice 2016 304 138
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect 2016 65 26
Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach 2016 165 97
La maladie thromboembolique veineuse : une pathologie souvent oubliée 2016 41 16
Pharmacogenomics of Oral Antithrombotic Drugs 2016 218 0
Genetics of clopidogrel poor-response 2016 128 0
Anticoagulants oraux directs (ACOD) : une aide à la prescription dans la pratique quotidienne 2016 52 17
Laboratory testing of Hemostasis 2015 68 61
Characterisation of the influences of aspirin-acetylation and glycation on human plasma proteins 2015 281 1
A focus on the role of platelets in liver regeneration: do platelet-endothelial cell interactions initiate the regenerative process? 2015 238 0
Aspirin-mediated acetylation of haemoglobin increases in presence of high glucose concentration and decreases protein glycation 2015 81 62
Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review 2015 228 4
The Human Diabetes Proteome Project (HDPP): The 2014 update 2015 119 64
Functional role of a polymorphism in the Pannexin1 gene in collagen-induced platelet aggregation 2015 163 8
Direct oral anticoagulants: efficacy and safety in patient subgroups 2015 288 168
Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study 2015 192 0
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor 2015 177 1
Reply to: "The role of platelets in liver regeneration - What don't we know?" 2015 97 0
Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma 2015 128 86
Fibrin degradation during sonothrombolysis – Effect of ultrasound, microbubbles and tissue plasminogen activator 2015 205 0
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants 2015 147 87
Suspicion of heparin-induced thrombocytopenia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing? 2015 224 2
Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies? 2015 271 1
How to manage prasugrel and ticagrelor in daily practice 2014 100 88
Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies 2014 217 0
Sputtered titanium oxynitride coatings for endosseous applications: Physical and chemical evaluation and first bioactivity assays 2014 322 1
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia 2014 255 1
Impact of high glucose concentration on aspirin-induced acetylation of human serum albumin: An in vitro study 2014 81 23
Evaluation of the GEM®PCL Plus point-of-care device for neonatal coagulation assessment: An observational study on cord blood 2014 175 2
Fibrinogen geneva II: a new congenitally abnormal fibrinogen alpha chain (Gly17Asp) with a review of similar mutations resulting in abnormal knob A. 2014 238 2
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism 2014 231 128
Antiplatelet Therapy: Targeting the TxA2 Pathway 2014 216 2
Role of paraoxonase-1 in CYP2C19 loss-of-function carriers 2014 241 0
Characterization of the platelet granule proteome: Evidence of the presence of MHC1 in alpha-granules 2014 342 3
Hémostase. Aspirine: une ou deux fois par jour? 2014 272 2
Antiplaquettaires et patients âgés : quelles molécules et quelles preuves ? 2013 217 1
Gestes invasifs et patients sous anticoagulants oraux : to bridge or not to bridge ? 2013 234 1
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013 2013 176 0
Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management 2013 233 0
Unraveling modulators of platelet reactivity incardiovascular patients using omics strategies: Towards anetwork biology paradigm 2013 248 217
Gestion péri-interventionnelle des nouveaux agents antiplaquettaires 2013 246 137
Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping 2013 150 0
Hémostase : nouveaux anticoagulants oraux : de la théorie à la pratique 2013 77 0
The Human Diabetes Proteome Project (HDPP): From network biology to targets for therapies and prevention 2013 232 15
Aspirin for venous thromboembolism prevention and treatment: a renewal? 2012 218 99
The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro 2012 177 0
Platelet proteomics 2012 209 2
Prevalence of poor biological response to clopidogrel: a systematic review 2012 160 0
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis 2012 222 0
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study 2012 256 3
Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management 2012 230 0
The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin 2011 212 0
Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study 2011 225 0
Connexin 37 limits thrombus propensity by downregulating platelet reactivity 2011 283 376
Surveillance biologique des héparines et du fondaparinux 2011 227 2
Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients 2011 249 1
Antiagregants plaquettaires : lequel, quand et pour qui ? 2010 197 0
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study 2010 220 0
Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis 2010 154 0
Evaluation de l'efficacité biologique du clopidogrel: génotype ou phénotype? 2010 169 0
Maladies cardiovasculaires, antiagrégants, anticoagulants et risque hémorragique 2010 230 0
Hémostase. Le point sur les nouveaux antithrombotiques 2010 218 0
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability 2010 255 0
Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided? 2009 195 0
Intercellular communication in atherosclerosis 2009 225 0
No influence of the VAMP8 rs1010 single nucleotide polymorphism on platelet functions in vitro 2009 201 0
Diagnosis of mild bleeding disorders 2009 266 923
Cell-derived microparticles in haemostasis and vascular medicine 2009 205 0
Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance 2009 160 0
Le concept de "resistance" a l'aspirine: mecanismes et pertinence clinique 2009 216 0
Assessing aspirin responsiveness using the Verify Now Aspirin assay 2008 241 1
Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis 2008 248 1
Laboratory-defined aspirin resistance and recurrent cardiovascular events 2008 220 0
Aspirin "resistance" and risk of cardiovascular morbidity 2008 191 1
Aspirin response variability assessed with the PFA-100 device 2008 231 0
Impending paradoxical embolism. When and how to treat? 2008 234 1
Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness 2008 204 0
18679 3225